What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Combination Product: RT-310 Implant for Investigational Treatment of Lower Urinary Tract Symptoms Secondary to BPH (Benign Prostatic Hyperplasia)”In the company’s words, NCT07928206 on ClinicalTrials.gov
- Tested for
- BPH (Benign Prostatic Hyperplasia) (2 trials), Benign Prostatic Hyperplasia (BPH), Lower Urinary Tract Symptoms
- Main trialPhase 2
- “A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of RT-310 (Paclitaxel) Protate Implant(s) for Treatment of Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH)”In the company’s words, NCT07928206 on ClinicalTrials.gov
Other drugs for BPH (Benign Prostatic Hyperplasia)
- H077 sustained-releaseShanghai Huilun Pharmaceutical Co., Ltd. · Phase 3
- Product DNN.65.21.005Ache Laboratorios Farmaceuticos S.A. · Phase 3
- FinasterideIl-Yang Pharm. Co., Ltd. · Phase 3
- TamsulosinIl-Yang Pharm. Co., Ltd. · Phase 3
- DTT106EMS · Phase 3
- Teverelix DPAntev Ltd. · Phase 2
Coming up1
- Dec 2028Phase 2 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 10 NovNew trial: none to Phase 2 · ClinicalTrials.gov NCT07928206
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Not yet recruiting | Dec 2028 | RELEASE Ph2 RT-310 BPH Study | |
| Phase 1/2Active, not recruiting | 26 Feb 2026 | RT-310 Safety and Feasibility BPH Study | |
| Phase 1Active, not recruiting | 6 May 2025 | RT-310 Dose Escalation BPH Study |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026